Administration of recombinant human GHRH-1,44-amide for 3 months reduces abdominal visceral fat mass and increases physical performance measures in postmenopausal women

Johannes D. Veldhuis, James M. Patrie, Kirsten Frick, Judith Y. Weltman, Arthur L. Weltman

Research output: Contribution to journalArticlepeer-review

16 Scopus citations

Fingerprint Dive into the research topics of 'Administration of recombinant human GHRH-1,44-amide for 3 months reduces abdominal visceral fat mass and increases physical performance measures in postmenopausal women'. Together they form a unique fingerprint.

Medicine & Life Sciences